[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591322":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":23,"locations":24,"responsibleParty":43,"collaborators":23,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":23,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":23,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":23,"overallStatus":27,"whyStopped":23,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Nuwacell Biotechnologies Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low Dose","EXPERIMENTAL","MRI-guided bilateral stereotactic cell implantation",[13],"Drug: Allogeneic dopaminergic neural precursor cell(NCR201)",{"label":15,"type":10,"description":11,"interventionNames":16},"High Dose",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Allogeneic dopaminergic neural precursor cell(NCR201)","Bilateral implantation",[15,9],null,[25],{"facility":26,"status":27,"city":28,"state":29,"zip":23,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"The First Affiliated Hospital of USTC","RECRUITING","Hefei","Anhui","China","CN",{"type":33,"coordinates":34},"Point",[35,36],117.28083,31.86389,{"lat":36,"lon":35},[39],{"name":26,"role":40,"phone":41,"phoneExt":23,"email":42},"CONTACT","0551-96512","ahslyyxcb@163.com",{"type":44,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100591322","phase-1-a-trial-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-ncr201-in-the-treatment-of-subjects-with-parkinsons-disease-100591322",false,"NCT06978920","A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease","A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson's Disease","Inclusion Criteria:\n\n* Ages between 40 and 75 years;\n* Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;\n* Disease history over 5 years;\n* Stable dose of dopamine treatment;\n* Able to undergo PET\u002FCT\u002FMRI detection;\n\nExclusion Criteria:\n\n* Patients who have previously undergone brain surgery;\n* Past use of stem cell therapy or participation in stem cell clinical research;\n* Cognitive impairment;\n* History of mental disorders;\n* Patients with other serious systemic diseases;\n* Past or current metastatic malignant tumors.","ALL","40 Years","75 Years",{"count":56,"type":57},48,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.",[63],"Parkinson Disease","2025-07-30",{"date":66,"type":67},"2025-08-01","ACTUAL",{"date":69,"type":67},"2025-06-06",{"date":71,"type":57},"2028-12-01",{"name":5,"class":6},1]